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Abstract
Background: To date, there is little information regarding management of patients with infective 
endocarditis (IE) that did not undergo an indicated surgery. Therefore, we aimed to evaluate prognosis 
of these patients treated with a long-term antibiotic treatment strategy, including oral long term suppres-
sive antibiotic treatment in five referral centres with a multidisciplinary endocarditis team.
Methods: This retrospective, multicenter study retrieved individual patient-level data from five referral 
centres in Spain. Among a total of 1797, 32 consecutive patients with IE were examined (median age 
72 years; 78% males) who had not undergone an indicated surgery, but received long-term antibiotic 
treatment (LTAT) and were followed by a multidisciplinary endocarditis team, between 2011 and 2019. 
Primary outcomes were infection relapse and mortality during follow-up.
Results: Among 32 patients, 21 had IE associated with prostheses. Of the latter, 8 had an ascend-
ing aorta prosthetic graft. In 24 patients, a switch to long-term oral suppressive antibiotic treatment 
(LOSAT) was considered. The median duration of LOSAT was 277 days. Four patients experienced  
a relapse during follow-up. One patient died within 60 days, and 12 patients died between 60 days and 
3 years. However, only 4 deaths were related to IE.
Conclusions: The present study results suggest that a LTAT strategy, including LOSAT, might be con-
sidered for patients with IE that cannot undergo an indicated surgery. After hospitalization, they should 
be followed by a multidisciplinary endocarditis team. (Cardiol J 2021; 28, 4: 566–578)
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Infective endocarditis (IE) is a severe, complex 
entity with high morbidity, inhospital mortality 
(20−30%) [1], and long-term mortality (~45%) [2], 
despite recent advances in diagnostic and thera-
peutic strategies [3–5]. The epidemiology of IE 
has changed [6–8] towards patients with multiple 
comorbidities, prostheses, devices, congenital 
heart diseases, or transcatheter procedures [9].
Cardiac surgery and antibiotic treatment are 
the cornerstones of IE treatment. According to 
current recommendations [10], more than 70% of 
patients with IE have an indication for surgery, but 
less than 50% finally undergo operations, due to 
surgical risk [11–13]. In-hospital mortality is high 
(~70%) among patients with surgery indicated 
not undergoing surgery IE (SINUS-IE). How-
ever, information is sparse regarding the clinical 
characteristics and long-term outcomes for these 
patients [14].
Clinical guidelines [10] do not specifically 
mention antibiotic treatment or a recommended 
treatment duration for patients with SINUS-IE. 
Oral antibiotics have shown to be effective for 
shortening intravenous treatment in selected 
cases of uncomplicated left-sided IE [15]; however, 
there is a lack information regarding oral long- 
-term antibiotic treatment (LTAT) in the context of 
SINUS-IE. Moreover, new imaging techniques [16], 
such as positron emission tomography/computed 
tomography (PET/CT) might play a role in moni-
toring responses and establishing an appropriate 
duration for LTAT [17, 18] in SINUS-IE.
We hypothesized that an approach managed 
by a multidisciplinary endocarditis team (MDET) 
that included individualized LTAT, long-term oral 
suppressive antibiotic treatment (LOSAT) when 
needed, and close follow-up might improve the 
long-term prognosis in SINUS-IE. Accordingly, this 
study aimed to evaluate the clinical characteristics 
and outcome of patients with SINUS-IE treated 
with long-term antibiotic regimens in 5 Spanish 
referral centres.
Methods
Study design and data collection
For this multicenter, retrospective, observa-
tional study, patient-level data was collected from 
local, prospective databases at 5 hospitals in Spain 
from January 2011 to January 2019. The 5 hospitals 
were referral centres for IE with cardiac surgery 
facilities. In addition, MDETs held regular meet-
ings to discuss and evaluate therapeutic strategies 
for patients with IE.
We included adult patients (age ≥ 18 years) 
with a definite diagnosis of IE (based on modified 
Duke criteria/European Society of Cardiology (ESC) 
criteria, modified in August 2015) and an indication 
for surgery or device extraction, according to clinical 
guidelines [10]. None of these patients underwent 
surgical procedures after an evaluation by the 
MDET. All these patients survived the index hospi-
talization with a plan established by the local MDET 
for long-term intravenous treatment (> 8 weeks) or 
LOSAT. Patients with fungal IE were excluded. For 
patients with relapses, only the episode in which 
the local committee decided to treat with LTAT was 
included. Patients that had been discharged with 
a plan for LTAT during follow-up were also included.
Data were obtained on demographics, clinical 
parameters, diagnostics (imaging, microbiological, 
and analytical parameters), and follow-up. A sim-
plified, standard case-report form was designed. 
Data were recorded anonymously and sent to the 
coordinating institution, where a database was 
created specifically for this study.
Definitions
Healthcare-associated endocarditis was 
defined elsewhere [19]. 
The Charlson comorbidity index [20] (not 
age adjusted) was used at admission to stratify 
overall co-morbidity.
Moderate or severe renal disease was de-
fined as an estimated glomerular filtration rate (based 
on CKD-EPI method) below 60 mL/min/1.73 m2 at 
admission.
Surgery was defined as the replacement or 
repair of the affected heart valve during the index 
hospitalization. 
Indications for surgery were adjudicated 
prospectively during the index episode by the local 
MDET, and they included: heart failure, embolic 
event prevention, and uncontrolled infection [10]. 
The EuroSCORE [21, 22] (logistic EuroSCORE I 
and EuroSCORE II) was calculated for all patients. 
For IEs related to a cardiovascular implantable 
electronic device (CIED), percutaneous device 
extraction was considered an indication for surgery.
Follow-up was defined as the period from the 
day antibiotic treatment for IE was started until 
death for any reason or the last follow-up. Data 
was collected at the end of intravenous antibiotic 
treatment, the beginning of oral antibiotic treat-
ment, when administered, and at the end of an oral 
antibiotic prescription, after completion.
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After discharge for IE, survivors were pro-
spectively followed at regular intervals. Each 
local MDET established the periodicity of blood 
cultures, clinical evaluations, and imaging (PET/CT 
and/or echocardiograms).
Long-term antibiotic treatment (LTAT) 
was defined as an intravenous or oral antibiotic 
regimen that exceeded the standard duration (usu-
ally < 8 weeks) of the established treatment for 
an episode of native, device-related, or prosthetic-
related IE. When patients were switched to oral 
treatment, the term long-term oral suppres-
sive antibiotic treatment (LOSAT) was used. 
The MDET determined, a priori, whether the 
duration of this treatment was time-defined or 
life-long. However, the treatment durations were 
re-evaluated at follow-ups. Durations were based 
on patient status evolution and the response to 
treatment, according to analytical, clinical, and 
cardiac imaging parameters. When intravenous 
treatment was required, an outpatient parenteral 
antibiotic therapy regimen was preferred.
Relapse was defined as a documented, posi-
tive blood culture, caused by the same microorgan-
ism that caused the initial IE, and being observed 
within the first year after completing the standard 
established antimicrobial treatment.
Mortality was defined as death from any 
cause during follow-up. The causes of IE-related 
mortality were: heart failure, stroke, uncontrolled 
infection, sudden death, and other causes attribut-
able to any IE complication.
Outcomes
Primary outcomes were: infection relapse and 
mortality at the last follow-up.
Ethics
This study was performed in compliance with 
the Helsinki Declaration and was approved by the 
local Ethics Committee of Hospital Universitari 
Germans Trias i Pujol (Badalona, Barcelona, Spain).
Statistical analysis
Categorical variables are expressed as ab-
solute numbers and percentages. Continuous 
variables are expressed as the mean and standard 
deviation (SD) or the median and 25–75 percentile 
(interquartile range [IQR]), according to the data 
distribution (normal or non-normal). Survival 
was evaluated with the Kaplan-Meier method 
and long-rank test. All analyses were performed 




Between January 2011 and January 2019, 1797 
patients with IE were identified in 5 participating 
centres. Among these, we identified 32 discharged 
patients with SINUS-IE managed with a LTAT 
strategy. The median follow-up time from diagnosis 
was 487 days (IQR: 332−1210 days). The baseline 
patient characteristics are detailed in Table 1. The 
mean age was 72.1 ± 17 years and 78% were males. 
Twenty-one (66%) patients had prosthetic valve en-
docarditis (PVE). Of these, 20 were left-sided and 
one was right-sided PVE. Eight patients suffered 
PVE before 1 year from valvular surgery (early 
PVE) and the other 13 corresponded to late PVE. 
Seven patients had CIED-related IE (Table 2). In 
these cases, the device was either not extracted 
or incompletely extracted, which were counter-
indications for surgery. Four patients had left-sided 
native valve IE; 17 (53%) had healthcare-associated 
IE, and 14 (43.7%) had a history of previous IE. Of 
note, 8 (25%) patients had ascending aorta pros-
thetic grafts (AAGs; Table 3). 
Most patients had comorbidities. The mean 
Charlson index was 5 points (range: 3−7). The main 
indication for surgery was uncontrolled infection 
(75%), and 18 patients had local complications. The 
main reasons for not undergoing surgery, despite 
the indication, were: high surgical risk (75%), 
surgeon refusal, due to an unaffordable technical 
risk (15.6%), and patient refusal (6.2%). 
Analysis of microbiological data, imaging 
data, treatment, and outcomes
Twenty-four (75%) patients underwent 
transesophageal echocardiography (TEE) and 20 
(63%) patients underwent a PET/CT. Remarkably, 
in 7 patients (5 with AAGs), the PET/CT estab-
lished the IE diagnosis after a previous negative 
or inconclusive TEE.
Blood cultures were positive in 94% of pa-
tients. The most prevalent microorganisms were 
coagulase-negative staphylococci (10/32, 31%) and 
Staphylococcus aureus (7/32, 22%). Blood cultures 
were negative in 2 patients that had previously 
received antibiotic treatment. Of these, one had 
previous cardiac surgery, and the surgery wound 
culture was positive for S. epidermidis; the other 
had undergone surgery 2 months prior for native 
aortic valve IE associated with S. sanguis; thus, 
this patient was treated for a relapse/early PVE.
The median duration of parenteral antibiotic 
treatment was 8 weeks (IQR: 6−12 weeks). In 
568 www.cardiologyjournal.org
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8 cases, only parenteral LTAT was administered, 
based on a decision by the local MDET. This 
treatment lasted 34 weeks (range: 8−34) and was 
administered in an outpatient or day care setting 
(Table 4).
Twenty-four (75%) patients were switched to 
LOSAT after prolonged (12 patients) or adjusted 
to guidelines (12 patients) parenteral administra-
tion. In 23 patients, the MDET initially established 
LOSAT as a life-long treatment, starting at dis-
charge. The median duration of LOSAT was 277 
days (IQR: 73−868).
Nine patients underwent PET/CTs to guide 
the duration and response to treatment. In these 
patients, the LOSAT was stopped, based on PET/ 
/CT information. None of these patients experi-
enced infection relapse.
Table 1. Baseline demographic, clinical, and  
microbiological characteristics of the study  
subjects.
Parameters Overall  
(n = 32)
Age [years] 72 ± 17
Male sex 25 (78.1)
Healthcare-associated IE 17 (53.1)
Type of infection
Prosthetic valve IE 21 (65.6)
Early/late PVE 8/13
Intracardiac device-related IE 7 (21.9)
Native IE 4 (12.5)
Clinical history-comorbidities
Previous cardiac surgery 19 (59.4)
Previous IE 14 (43.8)
Chronic renal failure 14 (43.8)
Hemodyalisis 3 (9.4)
Diabetes mellitus 9 (28.1)
COPD 5 (15.6)
Severe liver disease 4 (12.5)
Cancer 4 (12.5)
HIV 1 (3.1)




Hemoglobin [g/dL] 10.2 ± 2.02 
CRP [mg/L], median (IQR) 33 (12–124)
eGFR [mL/min/1.73 m2] 52.9 ± 24
Echocardiography-PET/CT
TEE performed 24 (75)
PET/CT performed 20 (62.5)
Control PET/CT performed 12 (37.5)
Local complication 18 (56.3)
Vegetation present 12 (37.5)




Coagulase-negative staphylococci 10 (31.3) 
Staphylococcus aureus 7 (21.9)
Streptococcus spp 4 (12.5)
Enterococcus faecalis 4 (12.5)
Non-HACEK Gram-negative bacili 2 (6.3)





Heart failure 5 (15.6)
Table 1 (cont.). Baseline demographic, clinical, 
and microbiological characteristics of the study  
subjects.
Parameters Overall  
(n = 32)




Uncontrolled infection 24 (75)
Local complication 18
Embolic 1 (3.1)
Device infection 6 (18.8)
EuroSCORE I (%), median (IQR) 32 (17-46)
EuroSCORE II (%), median (IQR) 9.1 (6.7-14)
Reasons for no surgery
Unaffordable surgical risk 24 (75)
Patient refusal 2 (6.3)
Intra-surgery clinical complication* 1 (3.1)
Surgeon refusal (technical risk) 5 (15.6)
Outcome
0 to 60-day mortality 1 (3.1)
Cumulative 3-year mortality 12 (37)
Related to IE 4 (12.5)
Relapses 4 (12.5)
Data are presented as the number (%) and mean ± 1 standard 
deviation, unless otherwise indicated. *Neurological complication 
during surgery without valve surgery attempted. COPD — chronic 
obstructive pulmonary disease; CRP — C-reactive protein; eGFR 
— estimated glomerular filtration rate; HIV — human immunodefi-
ciency virus; IE — infective endocarditis; IQR — interquartile range; 
PET/CT — positron emission tomography/computed tomography; 
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Long-term oral suppressive antibiotic treat-
ment comprised a variety of oral antimicrobial 
classes. In initial treatments, 9 patients received 
beta-lactams, 9 patients received trimethoprim-
sulfamethoxazole (TMP/SMX), 2 patients received 
clindamycin, and 4 patients received fluoroquinolo-
nes (levofloxacin). Others agents were combined 
with the initial treatment or were used during 
follow-up, including linezolid (n = 2) and rifampicin 
(combined with levofloxacin, n = 1). Four (17%) 
patients experienced adverse drug-related events, 
including thrombocytopenia (n = 2), associated 
with linezolid, and digestive intolerance (n = 1) and 
a skin disorder (n = 1), associated with TMP/SMX. 
Only 1 of these patients required definitive LOSAT 
discontinuation. In 2 cases, in vitro resistance was 
resolved with another antibiotic treatment option. 
Some antibiotic regimens and doses are described 
in Tables 2 and 3.
Four patients experienced infection relapses 
during follow-up. All had positive blood cultures, 
but no clinical repercussion. The median time to 
relapse was 144 days (IQR: 72−210). The first re-
lapse was a late PVE associated with Streptococcus 
viridans. An aortic abscess was treated with oral 
amoxicillin (3 g/day), which was stopped after 
1 year, due to clinical stability; subsequently, positive 
blood cultures were documented. Life-long amoxi-
cillin was re-started, and the patient is currently 
doing well in follow-up. The second relapse was 
a CIED-related IE, associated with coagulase-nega-
tive Staphylococcus and incomplete extraction of the 
CIED lead. The patient was switched to oral TMP/ 
/SMX. After 2 months, positive blood cultures were 
detected, but without clinical repercussion, and 
the same antibiotic regimen that was used in the 
follow-up. The third relapse was a prosthetic valve 
(Bentall surgery) IE, associated with coagulase-
-negative Staphylococcus. The patient was treated 
with TMP/SMX LOSAT, but after 5 months, the 
patient developed in vitro resistance to TMP/SMX. 
After switching to oral clindamycin, the IE showed 
a favourable evolution. The fourth relapse was an 
early PVE, associated with coagulase-negative 
Staphylococcus. The patient was switched to oral 
linezolid (600 mg bid). After 3 months, during 
treatment, positive blood cultures were detected, 
and the treatment was switched to intravenous 
vancomycin for 4 weeks. Subsequently, the patient 
was treated with oral TMP/SMX (160/800 mg bid), 
which was stopped after 1 year, due to stable infec-
tion and clinical stability and disease improvement, 
based on PET/CT.
The estimated overall survival rates were 
78% at 1 year and 62% at 3 years (Fig. 1). Only 
1 patient died within 60 days, due to an uncontrolled 
infection during treatment. Twelve patients died 
between 60 days and 3 years, but only 4 deaths 












Final status  
(follow-up, 
years)








91 Male CRF S. aureus No CMX 160/800 mg bid 
Ø 
LVF 500 mg QD 
Longlife
Alive (1.6)
88 Female Diabetes S. aureus Yes LVF 500 mg/2 days 
Longlife
Alive (6.6)
82 Male CRF, COPD S. epidermidis No LVF 250 mg/2 days 




93 Female CRF, hepatopathy Enterococcus 
faecalis




69 Male COPD, hepatopathy S. epidermidis Yes Amoxicilin 1 g TD 
Longlife
Alive (0.8)
CMX — cotrimoxazole; COPD — chronic obstructive pulmonary disease; CRF — chronic renal failure; LVF — levofloxacine; bid — bis in die 
(twice a day); QD — quaque die (once a day); TD — ter in die (three times a day)
570 www.cardiologyjournal.org
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cardiology Journal 2021, Vol. 28, No. 4
were related to IE (due to uncontrolled infection 
in 1 patient, stroke in 2 patients, and heart failure 
in 1 patient). After 3 years of follow-up, 3 more 
deaths occurred that were unrelated to IE. Of note, 
in the group with SINUS-IE that had AAGs, only 
1 IE-related death occurred after a previous relapse 
(Table 3), and in the CIED device IE group, 3 deaths 
occurred that were unrelated to IE (Table 2).
Discussion
According to available research, this study 
included the largest series (including left sided IE) 
to date in describing the experiences and outcomes 
of patients with SINUS-IE treated with LTAT, in-
cluding those that switched to LOSAT. All previous 
studies were small, retrospective studies or case 
reports (Table 5). An overall survival of 62% at 
3 years, and only 4 relapses were observed.
Successful IE treatment requires prolonged 
bactericidal antibiotic treatment and surgery to 
remove infected material and drain abscesses. 
Current indications for surgery in IE are well de-
fined in the American Heart Association and ESC 
guidelines [10, 23]. They include valve dysfunction 
that leads to heart failure, uncontrolled infection 
(defined as a paravalvular extension, abscess, or 
persistent bacteremia), and recurrent/high risk of 
embolism. More than 50% of patients with IE meet 
the surgical criteria, according to clinical guidelines 
[24], but of those, 20–40% do not undergo surgery 
due to high perioperative risk [11, 14, 25]. In-hos-
pital mortality is high in SINUS-IE, typically due to 
shock and heart failure; only one third of patients 
survive past the index hospitalization [14]. In the 
present study, among the patients with SINUS IE 
that were treated with LTAT and survived the acute 
phase of IE, the main indication for surgery was 
uncontrolled infection (75% of patients), including 
18 (56%) patients with local complications (mainly 
perianular abscesses) detected in imaging. 
Guideline recommendations concerning anti-
biotic treatments and durations are not sufficiently 
evidence-based for SINUS-IE, due to the lack of 
randomized controlled trials [9]. The standard 
treatment for IE is 2–6 weeks of intravenous 
antibiotic treatment. This treatment is suitable 
for classical, uncomplicated, prosthetic-, native-, 
or device-related IE, but clinical guidelines do 
not mention antibiotic treatment or durations for 
patients with SINUS-IE. Consequently, patients 
with SINUS-IE are treated according to local ex-
perience, in a heterogeneous manner.
In the present study, 7 patients with local 
complications received prolonged LTAT. A recent 
study described treating IE with dalbavancin [26], 
a long-acting lipoglycopeptide antibiotic with ex-
cellent anti-staphylococcal activity and a half-life 
of 346 h. This treatment might be an attractive 
option for staphylococcal-associated endocarditis, 
in patients with SINUS-IE that cannot tolerate oral 
antibiotic treatment. A recent case study showed 
a favourable outcome with dalvabancin [27]. In the 
present study, due to the retrospective design, no 
patients were treated with dalvabancin.
The role of oral antibiotic therapy in treating 
IE remains controversial [28]. Oral antibiotics 
have high bioavailability and have been effective 
in shortening intravenous treatment and treating 
selected cases of uncomplicated IE caused by 
susceptible organisms [15, 28−31]. Recently, an 
intervention study [32] demonstrated that a rapid 
switch to oral TMP/SMX reduced the hospital stay 
and mortality in S. aureus-associated IE, including 
patients with cardiac abscesses or persistent bacte-
remia. Oral LOSAT for patients with SINUS-IE has 
only been described in case reports [33], in case 
series for some specific situations (e.g., fungal IE 
[34], CIED--related IE [35, 36], aortic grafts [37]), 
and briefly, in some contemporary series [25] and 
reviews [9]. 
Prosthetic graft infection is a fatal complication 
after thoracic aorta replacement; early mortality 
was reported to be 25−42% [38]. In the present 
study, 8 patients with SINUS-IE that developed 
PVE after a previous surgery involving the aortic 
root and ascending aorta (Bentall procedure or 
ascending aorta graft replacement) were treated 
Figure 1. Survival in surgery indicated, but did not un-
dergo surgery for infective endocarditis patients treated 
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with LTAT. Five of these patients were treated 
orally (two life-long treatments), and only one 
death occurred during follow-up. The diagnosis and 
management of PVE after aortic root or ascending 
aorta graft surgery are difficult and require long- 
-term, combined antibiotic treatment and surgery, 
when possible [39]. In patients with inconclusive 
echocardiographic results, a combination of PET/ 
/CT and cardiac CT is recommended [40, 41] 
(among our 8 patients, 5 were diagnosed with 
PET/CT after inconclusive or negative TEEs). 
Consistent with some previous reports [37, 42−44], 
the present findings suggested that individualized 
LTAT might be effective (when there is no valvular 
dysfunction) in select patients with PVE compli-
cated with AAG infections that are unfit to undergo 
surgery. Another option could be conservative 
surgery with valvular replacement and AAG pres-
ervation. However, the risk of recurrence is high; 
thus, chronic antibiotic suppressive treatment has 
been recommended, in some cases [38].
Positron emission tomography/computed 
tomography is a functional molecular imaging 
technique that depicts metabolic activity. Several 
studies [16, 17, 41] have shown its utility for di-
agnosing PVE. Recently, ESC IE guidelines [10] 
have included abnormal activity around a prosthetic 
valve as a major criterion and embolic phenomena 
as a minor criterion for diagnosing PVE. In the pre-
sent study, PET/CT was performed as a diagnostic 
tool in 62.5% of patients. Additionally, PET/CT 
has shown promise in monitoring responses to 
antimicrobial treatment in PVE, as suggested in 
small observational studies [18]. On the other hand, 
sometimes, false-negative findings have been at-
tributed to low inflammatory activity at the time of 
imaging, caused by prolonged antibiotic therapy. In 
the present study, PET/CT was used to guide the 
cessation of LOSAT in 9 patients. Those patients 
had favourable outcomes, after antibiotic treatment 
was stopped, due to a reduction or termination of 
metabolic uptake detected with PET/CT. More 
large-scale studies are warranted to investigate 
this indication.
In the present study, 7 patients with CIED-
-related IE were treated with LOSAT. Of these, 
3 patients had incomplete percutaneous extractions, 
and the other 4 had comorbidities that counter-
indicated percutaneous extraction, as judged by 
the MDET. Of these 7 patients, only one experi-
enced a relapse, and no IE-related deaths occurred. 
LOSAT was also given to select patients with de-
vice-related IE that were ineligible for device removal 
(either surgical or percutaneous) or patients that 
experienced incomplete removal [45]. Currently, 
no comparable studies on LOSAT are available. 
Therefore, the optimal choice, dose, or duration 
of antibiotic treatment remain undefined; differ-
ent outcomes have been reported in the few small 
observational studies that were published [35, 36].
The 5 hospitals included in the present study 
had a MDET that was comprised of cardiac imag-
ing experts, cardiac surgeons, microbiologists, and 
infectious disease specialists. Previous studies 
showed that a team-based approach reduced the 
1-year mortality in a mixed cohort of medically 
and surgically managed patients with IE [46, 47]. 
Additionally, a recent study [48] showed improved 
survival in patients that were managed medically. 
The present study showed that close follow-up and 
individualized treatment, supported with cardiac 
imaging, could improve the long-term prognosis in 
patients with SINUS-IE treated with LTSAT includ-
ing LOSAT. Based on our experience, we propose 
an algorithm (Fig. 2) for guiding the management of 
patients with SINUS-IE and treatment with LOSAT.
Limitations of the study
This study had several limitations. First, 
antibiotic treatment was heterogeneous, because 
administration was at the discretion of the physi-
cian and the center, according to local protocols. 
Second, the definition of LOSAT was established ad 
hoc. Third, patient-level data were retrospective, 
pooled, and prospectively analyzed. Proposed algo-
rithm is based on our own local experience without 
previous supporting clinical evidence.
Conclusions
Surgery indicated not undergoing surgery 
IE remains a dreadful complication, and we lack 
evidence-driven management guidelines. Herein, 
it was shown that survivors could achieve a rea-
sonable long-term prognosis with an MDET-based, 
managed approach, with close follow-up, individu-
alized antibiotic treatment, including LOSAT, and 
guidance from new imaging techniques. More 
multicenter prospective studies are needed to 
validate the proposed algorithm and to establish an 
appropriate long-term strategy for treating patients 
with SINUS-IE.
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